Molecular cell biology of androgen receptor signalling

Bennett, Nigel C., Gardiner, Robert A., Hooper, John D., Johnson, David W. and Gobe, Glenda C. (2010) Molecular cell biology of androgen receptor signalling. International Journal of Biochemistry and Cell Biology, 42 6: 813-827. doi:10.1016/j.biocel.2009.11.013

Author Bennett, Nigel C.
Gardiner, Robert A.
Hooper, John D.
Johnson, David W.
Gobe, Glenda C.
Title Molecular cell biology of androgen receptor signalling
Journal name International Journal of Biochemistry and Cell Biology   Check publisher's open access policy
ISSN 1357-2725
Publication date 2010-06
Year available 2009
Sub-type Article (original research)
DOI 10.1016/j.biocel.2009.11.013
Volume 42
Issue 6
Start page 813
End page 827
Total pages 15
Place of publication Oxford, United Kingdom
Publisher Pergamon
Collection year 2011
Language eng
Abstract The classical action of androgen receptor (AR) is to regulate gene transcriptional processes via AR nuclear translocation, response element binding and recruitment of, or crosstalk with, transcription factors. AR also utilises non-classical, non-genomic mechanisms of signal transduction. These precede gene transcription or protein synthesis, and involve steroid-induced modulation of cytoplasmic or cell membrane-bound regulatory proteins. Despite many decades of investigation, the role of AR in gene regulation of cells and tissues remains only partially characterised. AR exerts most of its effects in sex hormone-dependent tissues of the body, but the receptor is also expressed in many tissues not previously thought to be androgen sensitive. Thus it is likely that a complex, more over-arching, role for AR exists. Each AR domain co-ordinates a multitude of individual and vital roles via a diverse array of interacting partner molecules that are necessary for cellular and tissue development and maintenance. Aberrant AR activity, promoted by mutations or binding partner misregulation, can present as many clinical manifestations including androgen insensitivity syndrome and prostate cancer. In the case of malignant prostate cancer, treatment generally revolves around androgen deprivation therapies designed to interfere with AR action and the androgen signalling axis. Androgen therapies for prostate cancer often fail, highlighting a real need for increased research into AR function. Copyright © 2009 Elsevier Ltd All rights reserved.
Keyword Androgen receptor
Steroid hormones
Prostate cancer
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Available online 19 November 2009. Published under Reviews.

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
Official 2011 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 86 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 95 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 20 Jun 2010, 00:05:21 EST